Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin

Current Topics in Microbiology and Immunology

Volumn 386, Issue , 2015, Pages 301-321

  Krammer, Florian ^a   Palese, Peter ^a   Steel, John ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; DNA VACCINE; EPITOPE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; MONOCLONAL ANTIBODY; NANOPARTICLE; NEUTRALIZING ANTIBODY; PEPTIDE VACCINE; RECOMBINANT VACCINE; VIRUS ANTIGEN; VIRUS SIALIDASE; VIRUS VECTOR; VIRUS ANTIBODY;

ANTIBODY COMBINING SITE; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; CELL MEMBRANE; COMPLEMENTARITY DETERMINING REGION; CROSS PROTECTION; DRUG DESIGN; DRUG FORMULATION; DRUG STRUCTURE; EMULSION; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; IMMUNOTHERAPY; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS A H2N2; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; RECEPTOR BINDING; VACCINE PRODUCTION; VIRUS NEUTRALIZATION; VIRUS STRAIN; ANIMAL; IMMUNOLOGY; VACCINATION;

ANIMALIA; ORTHOMYXOVIRIDAE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA VACCINES; VACCINATION;

EID: 84921503793     PISSN: 0070217X     EISSN: 21969965     Source Type: Book Series    
DOI: 10.1007/82_2014_408     Document Type: Article

References (95)

1. Beyer WE, McElhaney J, Smith DJ, Monto AS, Nguyen-Van-Tam JS, Osterhaus AD (2013) Cochrane re-arranged: support for policies to vaccinate elderly people against influenza. Vaccine 31:6030–6033. doi:S0264-410X(13)01339-X, 10.1016/j.vaccine.2013.09.063
2. Bommakanti G, Citron MP, Hepler RW et al (2010) Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc Natl Acad Sci USA 107:13701–13706. doi:10.1073/pnas.1007465107
3. Bommakanti G, Lu X, Citron MP et al (2012) Design of Escherichia coli-expressed stalk domain immunogens of H1N1 hemagglutinin that protect mice from lethal challenge. J Virol 86:13434–13444. doi:10.1128/JVI.01429-12
4. Brandenburg B, Koudstaal W, Goudsmit J et al (2013) Mechanisms of hemagglutinin targeted influenza virus neutralization. PLoS One 8:e80034. doi:10.1371/journal.pone.0080034
5. Brown LE, Murray JM, White DO, Jackson DC (1990) An analysis of the properties of monoclonal antibodies directed to epitopes on influenza virus hemagglutinin. Arch Virol 114:1–26
6. Bucasas KL, Franco LM, Shaw CA et al (2011) Early patterns of gene expression correlate with the humoral immune response to influenza vaccination in humans. J Infect Dis 203:921–929. doi:10.1093/infdis/jiq156
7. Caton AJ, Brownlee GG, Yewdell JW, Gerhard W (1982) The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 31:417–427. doi:10.1016/0092-8674(82)90135-0
8. CDC (2010) Estimates of deaths associated with seasonal influenza—United States, 1976–2007. MMWR Morb Mortal Wkly Rep 59:1057–1062.
9. Co MD, Cruz J, Takeda A, Ennis FA, Terajima M (2012) Comparison of complement dependent lytic, hemagglutination inhibition and microneutralization antibody responses in influenza vaccinated individuals. Hum Vaccin Immunother 8:1218–1222. doi:10.4161/hv.21025
10. Corti D, Lanzavecchia A (2013) Broadly neutralizing antiviral antibodies. Annu Rev Immunol 31:705–742. doi:10.1146/annurev-immunol-032712-095916
11. Corti D, Suguitan AL Jr, Pinna D et al (2010) Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 120:1663–1673. doi:10.1172/JCI41902
12. Corti D, Voss J, Gamblin SJ et al (2011) A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333:850–856. doi:10.1126/science.1205669
13. Dilillo DJ, Tan GS, Palese P, Ravetch JV (2014) Broadly neutralizing hemagglutinin stalkspecific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat Med 20:143–151. doi:10.1038/nm.3443
14. Dreyfus C, Laursen NS, Kwaks T et al (2012) Highly conserved protective epitopes on influenza B viruses. Science 337:1343–1348. doi:10.1126/science.1222908
15. Dreyfus C, Ekiert DC, Wilson IA (2013) Structure of a classical broadly neutralizing stem antibody in complex with a pandemic H2 influenza virus hemagglutinin. J Virol 87:7149–7154. doi:10.1128/JVI.02975-12
16. Du L, Jin L, Zhao G et al (2013) Identification and structural characterization of a broadly neutralizing antibody targeting a novel conserved epitope on the influenza virus H5N1 hemagglutinin. J Virol 87:2215–2225. doi:10.1128/JVI.02344-12
17. Ekiert DC, Bhabha G, Elsliger MA et al (2009) Antibody recognition of a highly conserved influenza virus epitope. Science 324:246–251. doi:10.1126/science.1171491
18. Ekiert DC, Friesen RH, Bhabha G et al (2011) A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333:843–850. doi:10.1126/science.1204839
19. Ekiert DC, Kashyap AK, Steel J et al (2012) Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature 489:526–532. doi:10.1038/nature11414
20. Ellebedy AH, Webby RJ (2009) Influenza vaccines. Vaccine 27(Suppl 4):D65–D68. doi:S0264-410X(09)01214-6, 10.1016/j.vaccine.2009.08.038
21. Fox JP, Cooney MK, Hall CE, Foy HM (1982) Influenzavirus infections in Seattle families, 1975–1979. II. Pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness. Am J Epidemiol 116:228–242
22. Friesen RH, Lee PS, Stoop EJ et al (2014) A common solution to group 2 influenza virus neutralization. Proc Natl Acad Sci USA 111:445–450. doi:10.1073/pnas.1319058110
23. Gerhard W, Yewdell J, Frankel ME, Webster R (1981) Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies. Nature 290:713–717
24. Glezen WP, Couch RB (1978) Interpandemic influenza in the Houston area, 1974–1976. N Engl J Med 298:587–592. doi:10.1056/NEJM197803162981103
25. Goff PH, Eggink D, Seibert CW, Hai R, Martínez-Gil L, Krammer F, Palese P (2013) Adjuvants and immunization strategies to induce influenza virus hemagglutinin stalk antibodies. PLoS One 8:e79194. doi:10.1371/journal.pone.0079194
26. Graves PN, Schulman JL, Young JF, Palese P (1983) Preparation of influenza virus subviral particles lacking the HA1 subunit of hemagglutinin: unmasking of cross-reactive HA2 determinants. Virology 126:106–116
27. Guo L, Zhang X, Ren L et al (2014) Human antibody responses to avian influenza A(H7N9) virus, 2013. Emerg Infect Dis 20:192–200. doi:10.3201/eid2002.131094
28. Hai R, Krammer F, Tan GS et al (2012) Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes. J Virol 86:5774–5781. doi:10.1128/JVI.00137-12
29. Hayden FG, Hay AJ (1992) Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol 176:119–130
30. Hayward AC, Fragaszy EB, Bermingham A et al (2014) Comparative community burden and severity of seasonal and pandemic influenza: results of the Flu Watch cohort study. Lancet Respir Med 2(6):445–454. doi: 10.1016/52213-2600(14)70034-7
31. Itoh Y, Shinya K, Kiso M et al (2009) In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460:1021–1025. doi:10.1038/nature08260
32. Janulíková J, Staneková Z, Mucha V, Kostolansky´ F, Varecˇková E (2012) Two distinct regions of HA2 glycopolypeptide of influenza virus hemagglutinin elicit cross-protective immunity against influenza. Acta Virol 56:169–176
33. Jegaskanda S, Job ER, Kramski M et al (2013) Cross-reactive influenza-specific antibodydependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J Immunol 190:1837–1848. doi:10.4049/jimmunol.1201574
34. Kanekiyo M, Wei CJ, Yassine HM et al (2013) Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature. doi:10.1038/nature12202
35. Kashyap AK, Steel J, Oner AF et al (2008) Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci USA 105:5986–5991
36. Kashyap AK, Steel J, Rubrum A et al (2010) Protection from the 2009 H1N1 pandemic influenza by an antibody from combinatorial survivor-based libraries. PLoS Pathog 6:e1000990. doi:10.1371/journal.ppat.1000990
37. Katz JM, Hancock K, Xu X (2011) Serologic assays for influenza surveillance, diagnosis and vaccine evaluation. Expert Rev Anti Infect Ther 9:669–683. doi:10.1586/eri.11.51
38. Krammer F, Palese P (2013) Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol 3:521–530. doi:10.1016/j.coviro.2013.07.007
39. Krammer F, Palese P (2014) Universal influenza virus vaccines: need for clinical trials. Nat Immunol 15:3–5. doi:10.1038/ni.2761
40. Krammer F, Pica N, Hai R, Tan GS, Palese P (2012) Hemagglutinin stalk-reactive antibodies are boosted following sequential infection with seasonal and pandemic H1N1 influenza virus in mice. J Virol 86:10302–10307. doi:10.1128/JVI.01336-12
41. Krammer F, Pica N, Hai R, Margine I, Palese P (2013) Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol 87:6542–6550. doi:10.1128/JVI.00641-13
42. Krammer F, Hai R, Yondola M et al (2014a) Assessment of influenza virus hemagglutinin stalkbased immunity in ferrets. J Virol 88:3432–3442. doi:10.1128/JVI.03004-13
43. Krammer F, Margine I, Hai R et al (2014b) H3 Stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge. J Virol 88:2340–2343. doi:10.1128/JVI.03183-13
44. Krause JC, Tsibane T, Tumpey TM, Huffman CJ, Basler CF, Crowe JE Jr (2011) A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. J Virol 85:10905–10908. doi:10.1128/JVI.00700-11
45. Lee PS, Yoshida R, Ekiert DC, Sakai N, Suzuki Y, Takada A, Wilson IA (2012) Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity. Proc Natl Acad Sci USA 109:17040–17045. doi:10.1073/pnas.1212371109
46. Li GM, Chiu C, Wrammert J et al (2012) Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc Natl Acad Sci USA 109:9047–9052. doi:10.1073/pnas.1118979109
47. Li S, Nakaya HI, Kazmin DA, Oh JZ, Pulendran B (2013) Systems biological approaches to measure and understand vaccine immunity in humans. Semin Immunol 25:209–218. doi:S1044-5323(13)00032-8, 10.1016/j.smim.2013.05.003
48. Lu Y, Welsh JP, Swartz JR (2014) Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines. Proc Natl Acad Sci USA 111:125–130. doi:10.1073/pnas.1308701110
49. Margine I, Hai R, Albrecht RA et al (2013a) H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and mice. J Virol 87:4728–4737. doi:10.1128/JVI.03509-12
50. Margine I, Krammer F, Hai R et al (2013b) Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. J Virol 87:10435–10446. doi:10.1128/JVI.01715-13
51. McNeil S, Shinde V, Andrew M, et al (2014) Interim estimates of 2013/2014 influenza clinical severity and vaccine effectiveness in the prevention of laboratory-confirmed influenza-related hospitalisation. Euro Surveill Mar 6; 19(9). pii 20729.
52. Miller MS, Gardner TJ, Krammer F, Aguado LC, Tortorella D, Basler CF, Palese P (2013a) Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis. Sci Transl Med 5:198ra107. doi:10.1126/scitranslmed.3006637
53. Miller MS, Tsibane T, Krammer F, Hai R, Rahmat S, Basler CF, Palese P (2013b) 1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans. J Infect Dis 207:98–105. doi:10.1093/infdis/jis652
54. Moody MA, Zhang R, Walter EB et al (2011) H3N2 influenza infection elicits more crossreactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination. PLoS One 6:e25797. doi:10.1371/journal.pone.0025797
55. Muthuri SG, Venkatesan S, Myles PR et al (2014) Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2(5):395–404. doi: 10.1016/52213-2600(14)70041-4
56. Nakamura G, Chai N, Park S et al (2013) An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies. Cell Host Microbe 14:93–103. doi:10.1016/j.chom.2013.06.004
57. Neumann G, Noda T, Kawaoka Y (2009) Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 459:931–939. doi:10.1038/nature08157
58. Ohshima N, Iba Y, Kubota-Koketsu R, Asano Y, Okuno Y, Kurosawa Y (2011) Naturally occurring antibodies in humans can neutralize a variety of influenza virus strains, including H3, H1, H2, and H5. J Virol 85:11048–11057. doi:10.1128/JVI.05397-11
59. Okuno Y, Isegawa Y, Sasao F, Ueda S (1993) A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol 67:2552–2558
60. Okuno Y, Matsumoto K, Isegawa Y, Ueda S (1994) Protection against the mouse-adapted A/FM/ 1/47 strain of influenza A virus in mice by a monoclonal antibody with cross-neutralizing activity among H1 and H2 strains. J Virol 68:517–520
61. Osterholm MT, Kelley NS, Sommer A, Belongia EA (2012) Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 12:36–44. doi:http://dx.doi.org/10.1016/S1473-3099(11)70295-X
62. Palese P, Wang TT (2011) Why do influenza virus subtypes die out? A hypothesis. MBio 2. doi:10.1128/mBio.00150-11
63. Pica N, Hai R, Krammer F et al (2012) Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc Natl Acad Sci USA 109:2573–2578. doi:10.1073/pnas.1200039109
64. Polakova K, Russ G, Styk B (1978) Antigenic glycopolypeptides HA1 and HA2 of influenza virus haemagglutinin. I. Gel filtration in 6 M guanidine hydrochloride. Acta Virol 22:362–370
65. Renegar KB, Small PA Jr (1991) Immunoglobulin A mediation of murine nasal anti-influenza virus immunity. J Virol 65:2146–2148
66. Russ G, Styk B, Polakova K (1978a) Antigenic glycopolypeptides HA1 and HA2 of influenza virus haemagglutinin. II. Reactivity with rabbit sera against intact virus and purified undissociated haemagglutinin. Acta Virol 22:371–382
67. Russ G, Styk B, Polakova K (1978b) Radioimmunoassay of influenza A virus haemagglutinin. I. Preparation and properties of radioactive 125I-labelled bromelain-released haemagglutinin. Acta Virol 22:1–10
68. Sagawa H, Ohshima A, Kato I, Okuno Y, Isegawa Y (1996) The immunological activity of a deletion mutant of influenza virus haemagglutinin lacking the globular region. J Gen Virol 77 (Pt 7):1483–1487
69. Samson M, Pizzorno A, Abed Y, Boivin G (2013) Influenza virus resistance to neuraminidase inhibitors. Antiviral Res 98:174–185. doi:S0166-3542(13)00068-5, 10.1016/j.antiviral.2013.03.014
70. Schneemann A, Speir JA, Tan GS, Khayat R, Ekiert DC, Matsuoka Y, Wilson IA (2012) A viruslike particle that elicits cross-reactive antibodies to the conserved stem of influenza virus hemagglutinin. J Virol 86:11686–11697. doi:10.1128/JVI.01694-12
71. Seibert CW, Rahmat S, Krause JC et al (2013) Recombinant IgA is sufficient to prevent influenza virus transmission in guinea pigs. J Virol 87:7793–7804. doi:10.1128/JVI.00979-13
72. Smirnov YA, Lipatov AS, Gitelman AK, Okuno Y, Van Beek R, Osterhaus AD, Claas EC (1999) An epitope shared by the hemagglutinins of H1, H2, H5, and H6 subtypes of influenza A virus. Acta Virol 43:237–244
73. Steel J, Lowen AC, Wang TT, et al (2010) Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio 1. doi:10.1128/mBio.00018-10
74. Subbarao K, Matsuoka Y (2013) The prospects and challenges of universal vaccines for influenza. Trends Microbiol 21:350–358. doi:S0966-842X(13)00074-7, 10.1016/j.tim.2013.04.003
75. Sui J, Hwang WC, Perez S et al (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16:265–273. doi:10.1038/nsmb.1566
76. Sui J, Sheehan J, Hwang WC et al (2011) Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza a antibodies. Clin Infect Dis 52:1003–1009. doi:10.1093/cid/cir121
77. Talaat KR, Luke CJ, Khurana S et al (2014) A live attenuated H5N1 vaccine induces long-term immunity in the absence of a primary antibody response. J Infect Dis. doi:10.1093/infdis/ jiu123
78. Tan GS, Krammer F, Eggink D, Kongchanagul A, Moran TM, Palese P (2012) A pan-H1 antihemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo. J Virol 86:6179–6188. doi:10.1128/JVI.00469-12
79. Terajima M, Cruz J, Co MD et al (2011) Complement-dependent lysis of influenza a virus-infected cells by broadly cross-reactive human monoclonal antibodies. J Virol 85:13463–13467. doi:10.1128/JVI.05193-11
80. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K (2004) Influenza-associated hospitalizations in the United States. J Am Med Assoc 292:1333–1340. doi:10.1001/jama.292.11.1333
81. Thomson CA, Wang Y, Jackson LM et al (2012) Pandemic H1N1 influenza infection and vaccination in humans induces cross-protective antibodies that target the hemagglutinin stem. Front Immunol 3:87. doi:10.3389/fimmu.2012.00087
82. Throsby M, van den Brink E, Jongeneelen M et al (2008) Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS ONE 3:e3942
83. Tricco AC, Chit A, Soobiah C et al (2013) Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Med 11:153. doi:10.1186/1741-7015-11-153
84. Wang TT, Tan GS, Hai R et al (2010a) Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Nat Acad Sci USA 107:18979–18984. doi:10.1073/pnas.1013387107
85. Wang TT, Tan GS, Hai R, Pica N, Petersen E, Moran TM, Palese P (2010b) Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog 6:e1000796. doi:10.1371/journal.ppat.1000796
86. Wei CJ, Boyington JC, McTamney PM et al (2010) Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329:1060–1064. doi:10.1126/science.1192517
87. Weis W, Brown JH, Cusack S, Paulson JC, Skehel JJ, Wiley DC (1988) Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature 333:426–431. doi:10.1038/333426a0
88. Whittle JR, Zhang R, Khurana S et al (2011) Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci USA 108:14216–14221. doi:10.1073/pnas.1111497108
89. Whittle JR, Wheatley AK, Wu L et al (2014) Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig heavy chain lineages. J Virol. doi:10.1128/JVI.03422-13
90. Wilson IA, Skehel JJ, Wiley DC (1981) Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature 289:366–373
91. Wrammert J, Smith K, Miller J et al (2008) Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453:667–671. doi:10.1038/nature06890
92. Wrammert J, Koutsonanos D, Li GM et al (2011) Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 208:181–193. doi:10.1084/jem.20101352
93. Xu R, Krause JC, McBride R, Paulson JC, Crowe JE Jr, Wilson IA (2013) A recurring motif for antibody recognition of the receptor-binding site of influenza hemagglutinin. Nat Struct Mol Biol 20:363–370. doi:10.1038/nsmb.2500
94. Yoshida R, Igarashi M, Ozaki H et al (2009) Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. PLoS Pathog 5:e1000350. doi:10.1371/journal.ppat.1000350
95. Zhu X, Guo YH, Jiang T et al (2013) A unique and conserved neutralization epitope in H5N1 influenza viruses identified by an antibody against the A/Goose/Guangdong/1/96 hemagglutinin. J Virol 87:12619–12635. doi:10.1128/JVI.01577-13